Germany Post-Traumatic Stress Disorder (PTSD) Market, By Type (Dissociative PTSD, Uncomplicated PTSD, Comorbid PTSD, Others), Treatment Type (Medication, Psycotherapy, Software Devices), Route of Administration (Oral, Parentral, Others), Age Group (Children, Adults, Geriatric), End User (Hospitals, Outpatient Clinics, Mental Health Centers, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) - Industry Trends and Forecast to 2030.
Germany Post-Traumatic Stress Disorder (PTSD) Market Analysis and Insights
Post-traumatic stress disorder (PTSD) is a mental health condition triggered by a terrifying event — either experiencing it or witnessing it. Symptoms may include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Most people who go through traumatic events may have temporary difficulty adjusting and coping, but with time and good self-care, they usually get better. If the symptoms get worse and last for months or even years and interfere with day-to-day functioning, then it is said to have PTSD. Getting effective treatment after PTSD symptoms develop can be critical to reducing symptoms and improving function.
The Germany post-traumatic stress disorder (PTSD) market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.4% in the forecast period of 2023 to 2030 and is expected to reach USD 210.44 million by 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2020-2015)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Type (Dissociative PTSD, Uncomplicated PTSD, Comorbid PTSD, Others), Treatment Type (Medication, Psycotherapy, Software Devices), Route of Administration (Oral, Parentral, Others), Age Group (Children, Adults, Geriatric), End User (Hospitals, Outpatient Clinics, Mental Health Centers, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
Germany
|
|
Market Players Covered
|
AbbVie Inc., Viatris Inc, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Aurobindo Pharma., AstraZeneca, Cipla Inc., Lupin, Accord Healthcare GmbH, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., and GlaxoSmithKline Group of Companies. Teva Pharmaceutical Industries Ltd., Alkermes. And Novartis AG among others.
|
Market Definition of Germany Post-Traumatic Stress Disorder (PTSD) Market
Post-traumatic stress disorder (PTSD) is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event.
It is the complex somatic, cognitive, affective, and behavioral effects of psychological trauma. It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.
Post-traumatic stress disorder (PTSD) treatment help to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition.
The rising prevalence of Post-traumatic stress disorder (PTSD) and technological advancements in diagnosis and treatment of PTSD in recent years is boosting the market growth while high treatment cost and adverse effects associated with treatment are working as restrain for the Germany Post-Traumatic Stress Disorder (PTSD) Market.
Germany Post-Traumatic Stress Disorder (PTSD) Market Dynamics
Drivers
Rising prevalence of PTSD.
Post-Traumatic Stress Disorder (PTSD) is a complex physical, cognitive, emotional, and behavioral consequence of psychological trauma. It is characterized by intrusive thoughts, nightmares, and flashbacks to past traumatic events, avoidance of traumatic reminders, hypervigilance, and sleep disturbance, all of which contribute to significant social, occupational, and interpersonal dysfunction.
PTSD is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape, or who have been threatened with death, sexual violence, or serious injury.
As a result, an increasing number of PTSD cases every year calls for the need for improved diagnostic processes and techniques for the treatment of PTSD patients.
Thus, due to a rising prevalence of PTSD, it is expected to act as a driving factor for market growth.
Technological advancements in the diagnosis and treatment of PTSD.
Various technologies, including heart rate monitors, electroencephalography (EEG), audio recorders, and eye-tracking peripherals, are now being used to capture and analyze neurological and physiological data to identify markers for the condition of PTSD.
Video conferencing is emerging as a viable method for providing psychiatric care and individual and group-based trauma interventions within underserved and geographically remote populations. Exposure therapy is an effective treatment for PTSD. Exposure therapy is another type of therapy that decreases PTSD symptoms through imaginal exposure (i.e., vividly imaging the feared object, situation, or activity) aimed at helping individuals overcome, rather than avoid, fear- and psychological distress-inducing stimuli.
The increasing incidence of PTSD
PTSD is a clinically diagnosed condition that occurs in about 20% of all individuals who experience or witness a traumatic event that involves the actual or possible threat of death, violence, or serious injury. Examples of traumatic events include experiencing or witnessing a natural disaster, serious accident, terrorist act, war/combat, rape, or being threatened with death, sexual violence, or serious injury.
The increase in the number of incidences every year is thus encouraging manufacturers' government officials to introduce innovative diagnostic techniques, which is expected to boost the market growth in upcoming years.
Hence, the rising number of new incidences of PTSD every year is expected to act as a driver for the market's growth.
Increased awareness among patients and doctors regarding therapies for PTSD
Increased awareness leads to an increase in the treatments and diagnoses of the patients. At the same time, early detection of PTSD will help therapists who are specialized in PTSD to ensure a good recovery. Many people with PTSD often deal with negative thoughts and feelings, which can greatly affect their emotional health and well-being. Many people with PTSD may feel a sense of guilt or responsibility for their trauma. Thus, increasing awareness of PTSD helps patients to get the right treatment.
Hence, the increased awareness among patients and doctors regarding therapies for PTSD is expected to act as a driver for the growth of the market.
Restraints
High cost of the treatment
Post-traumatic stress disorders (PTSD) pose a high burden for individuals and societies. Although prevalence rates are rather low, high co-occurrence rates and overall impairments cause deleterious suffering and significant treatment costs. The cost of treating PTSD can vary significantly. Some patients can get very low-cost care from the government, but many choose to get private care and pay out of pocket, which can easily add up to thousands in a year.
Thus, the high cost of treatment will is expected to act as a major restraining factor for the growth of the market.
Side effects associated with PTSD treatment
There are several types of antidepressant drugs that can be used to treat PTSD, Antidepressants have several side effects. They vary depending on the medication and affect people differently. The most common side effects include: dry mouth, nausea, constipation, diarrhea, headache, drowsiness, insomnia, high or low blood pressure, light-headedness, sexual difficulties, changes in appetite that can lead to weight gain or loss, excessive sweating—venlafaxine, blurry vision caused by drug nefazodone and severe liver damage caused by drug nefazodone
Risk of severe mood and behavior changes, including suicidal thoughts in some patients (Young adults may be at a higher risk for this side effect.) Hence, the side effects associated with PTSD treatment is expected to hamper the market growth.
Opportunities/Challenges
Rising healthcare expenditure
The expense of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization for the healthcare system. In particular, there is a strong association between the whole income level of a country and how much the country's population spends on its healthcare.
The psychotherapies, or pharmacotherapies, are beneficial for individuals with PTSD, and early preventive approaches could prevent high incremental costs.
The costs are constantly increasing year by year at a small rate, which can be explained by overall increases in healthcare expenditures within the German statutory healthcare system
Growing healthcare expenditure is expected to increase the availability of Post-Traumatic Stress Disorder treatment drugs for better patient treatment with fewer human medical errors. Hence, the massive healthcare expenditure is a favorable factor and is expected to create a significant opportunity for the growth of the Post-Traumatic Stress Disorder market.
Rising approvals of drugs
The rising approvals of drugs for Post-traumatic stress disorder by The Federal Institute for Drugs and Medical Devices (BfArM) and experts contribute their knowledge to the scientific committees of the European Medicines Agency (EMA), among others. Throughout the EU and internationally, BfArM significantly contributes to the supply of safe and effective medicines.
The Federal Institute for Drugs and Medical Devices has increased the approval of drugs to treat post-traumatic stress disorder. These approval received for PTSD drugs would result in the medicine being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of medicines to the developing markets in the Germany region. Hence, the rise in product approvals is expected to propel market growth.
Patent expiry of drugs
Patent expiry of innovator pharmaceutical companies changes the market dynamics that brought the increased production of generics by rival companies after the expiry of the patent of the product, which affects the competitive market price changes, pressures, and changes in sales volumes and profit of multinational innovator pharmaceutical companies
The rising number of generic drugs in the market enhances the challenge among the market players that impacts the revenue of the market by reduction of existing drug prices.
The termination of patents would result in fewer chances of product approval and the rise of generic drugs in the market, which may act as a challenge to the growth of the market.
Recent Developments
- In March 2022, AbbVie and Gedeon Richter Plc. (Richter) announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and included several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA. This collaboration helps the company to expand its business and find new and innovative solutions and discoveries in terms of neurological disorders.
Germany Post-Traumatic Stress Disorder (PTSD) Market
Germany post-traumatic stress disorder (PTSD) market is segmented into type, treatment type, route of administration, age group, end user and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Dissociative PTSD
- Uncomplicated PTSD
- Comorbid PTSD
- Others
On the basis of type, the Germany post-traumatic stress disorder (PTSD) market is segmented into dissociative PTSD, uncomplicated PTSD, comorbid PTSD, and others.
Treatment Type
- Medication
- Psychotherapy
- Software Devices
On the basis of procedure type, the Germany post-traumatic stress disorder (PTSD) market is segmented into medication, psychotherapy, and software devices.
Route of Administration
- Oral
- Parentral
- Others
On the basis of the route of administration, the Germany post-traumatic stress disorder (PTSD) market is segmented into oral, parenteral, and others.
Age Group
- Children
- Adult
- Geriatrics
On the basis of Age group, the Germany post-traumatic stress disorder (PTSD) market is segmented into children, adults, and geriatrics.
End User
- Hospitals
- Outpatient Clinics
- Mental Health Centers
- Home Healthcare
- Others
On the basis of end-user, the Germany post-traumatic stress disorder (PTSD) market is segmented into hospitals, outpatient clinics, mental health centers, home healthcare, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of the distribution channel, the Germany post-traumatic stress disorder (PTSD) market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Competitive Landscape and Germany Post-Traumatic Stress Disorder (PTSD) Market Share Analysis
Germany post-traumatic stress disorder (PTSD) market competitive landscape provides details of a competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the vagus nerve stimulation market.
Some of the major players operating in the Germany Post-Traumatic Stress Disorder (PTSD) Market are AbbVie Inc., Viatris Inc, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Aurobindo Pharma., AstraZeneca, Cipla Inc., Lupin, Accord Healthcare GmbH, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., and GlaxoSmithKline Group of Companies. Teva Pharmaceutical Industries Ltd., Alkermes., and Novartis AG among others.
SKU-